Caffeine is one of the most widespread psychotropic substances in the world. It exerts multiple effects on the brain including adenosine receptor antagonism, and thereby has been found to modulate aspects of cognition, including attention, in animal models and in healthy human volunteers. This review considers what is known of the effects of caffeine on symptoms and cognitive functions in attention-deficit hyperactivity disorder (ADHD), a prototypical disorder of cognitive dysfunction. We consider the merits of investigating further caffeine’s therapeutic potential as a monotherapy or as an adjunctive agent in ADHD. The potential benefits of re-opening a dialogue regarding the use of caffeine in ADHD clinical practice are highlighted, along with potential implications for the use of adenosine receptor antagonists in ADHD and other disorders characterised by cognitive impairment.
ArnaudMJ (1987) The pharmacology of caffeine. Prog Drug Res Fortschritte Arzneimittelforschung Prog Rech Pharm31: 273–313.
2.
ArnoldLEChristopherJHuestisR. (1978) Methylphenidate vs dextroamphetamine vs caffeine in minimal brain dysfunction: Controlled comparison by placebo washout design with Bayes’ analysis. Arch Gen Psychiatry35: 463–473.
3.
AshersonPChenWCraddockB. (2007) Adult attention-deficit hyperactivity disorder: Recognition and treatment in general adult psychiatry. Br J Psychiatry J Ment Sci190: 4–5.
4.
BabuKMChurchRJLewanderW (2008) Energy drinks: The new eye-opener for adolescents. Clin Pediatr Emerg Med9: 35–42.
5.
BaerRA (1987) Effects of caffeine on classroom behavior, sustained attention, and a memory task in preschool children. J Appl Behav Anal20: 225–234.
6.
BauerAHolschbachMHMeyerPT. (2003) In vivo imaging of adenosine A1 receptors in the human brain with [18F]CPFPX and positron emission tomography. NeuroImage19: 1760–1769.
7.
BernsteinGACarrollMEThurasPD. (2002) Caffeine dependence in teenagers. Drug Alcohol Depend66: 1–6.
8.
BodenmannSHohoffCFreitagC. (2012) Polymorphisms of ADORA2A modulate psychomotor vigilance and the effects of caffeine on neurobehavioural performance and sleep EEG after sleep deprivation. Br J Pharmacol165: 1904–1913.
9.
Bolea-AlamañacBNuttDJAdamouM.: Consensus Group (2014) Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: Update on recommendations from the British Association for Psychopharmacology. J Psychopharmacol Oxf Engl28: 179–203.
10.
BoryczJPereiraMFMelaniA. (2007) Differential glutamate-dependent and glutamate-independent adenosine A1 receptor-mediated modulation of dopamine release in different striatal compartments. J Neurochem101: 355–363.
11.
BroderickPBenjaminAB (2004) Caffeine and psychiatric symptoms: A review. J Okla State Med Assoc97: 538–542.
12.
CaballeroMNúñezFAhernS. (2011) Caffeine improves attention deficit in neonatal 6-OHDA lesioned rats, an animal model of attention deficit hyperactivity disorder (ADHD). Neurosci Lett494: 44–48.
13.
CaisleyHMüllerU (2012) Adherence to medication in adults with attention deficit hyperactivity disorder and pro re nata dosing of psychostimulants: A systematic review. Eur Psychiatry J Assoc Eur Psychiatr27: 343–349.
14.
ChenJ-FEltzschigHKFredholmBB (2013) Adenosine receptors as drug targets — what are the challenges?Nat Rev Drug Discov12: 265–286
15.
ClementzGLDaileyJW (1988) Psychotropic effects of caffeine. Am Fam Physician37: 167–172.
16.
ConnersCK (1975) A placebo-crossover study of caffeine treatment of hyperkinetic children. Int J Ment Health4: 132–143.
17.
ConnersCK (1979) The acute effects of caffeine on evoked response, vigilance, and activity level in hyperkinetic children. J Abnorm Child Psychol7: 145–151.
18.
CorteseSHoltmannMBanaschewskiT.; European ADHD Guidelines Group (2013) Practitioner review: Current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents. J Child Psychol Psychiatry54: 227–246.
19.
CunhaRAAgostinhoPM (2010) Chronic caffeine consumption prevents memory disturbance in different animal models of memory decline. J Alzheimers Dis20: S95–S116.
20.
CunhaRAFerréSVaugeoisJ-M. (2008) Potential therapeutic interest of adenosine A2A receptors in psychiatric disorders. Curr Pharm Des14: 1512–1524.
21.
DalbyJT (1985) Will population decreases in caffeine consumption unveil attention deficit disorders in adults?Med Hypotheses18: 163–167.
22.
Del CampoNChamberlainSRSahakianBJ. (2011) The roles of dopamine and noradrenaline in the pathophysiology and treatment of attention-deficit/hyperactivity disorder. Biol Psychiatry69: e145–e157.
23.
DoshTHelmbrechtTAnestisJ. (2010) A comparison of the associations of caffeine and cigarette use with depressive and ADHD symptoms in a sample of young adult smokers. J Addict Med4: 52–54.
24.
DungoRDeeksED (2013) Istradefylline: First global approval. Drugs73: 875–882.
25.
EskelinenMHKivipeltoM (2010) Caffeine as a protective factor in dementia and Alzheimer’s disease. J Alzheimers Dis20: S167–S174.
26.
EspinosaJRochaANunesF. (2013) Caffeine consumption prevents memory impairment, neuronal damage, and adenosine A2A receptors upregulation in the hippocampus of a rat model of sporadic dementia. J Alzheimers Dis34: 509–518.
27.
FaraoneSVBiedermanJMickE (2006) The age-dependent decline of attention deficit hyperactivity disorder: A meta-analysis of follow-up studies. Psychol Med36: 159–165.
28.
FastbomJPazosAProbstA. (1987) Adenosine A1 receptors in the human brain: A quantitative autoradiographic study. Neuroscience22: 827–839.
29.
FerreSCiruelaFBoryczJ. (2008) Adenosine A1-A2A receptor heteromers: New targets for caffeine in the brain. Front Biosci J Virtual Libr13: 2391–2399.
30.
FerréSCiruelaFQuirozC. (2007) Adenosine receptor heteromers and their integrative role in striatal function. Sci World J7: 74–85.
31.
FirestonePDaveyJGoodmanJT. (1978) The effects of caffeine and methylphenidate on hyperactive children. J Am Acad Child Psychiatry17: 445–456.
32.
FrasI (1974) Letter: Alternating caffeine and stimulants. Am J Psychiatry131: 28–229.
33.
FredholmBB (1995) Adenosine, adenosine receptors and the actions of caffeine. Pharmacol Toxicol76: 93–101.
34.
FredholmBBBättigKHolménJ. (1999) Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev51: 83–133.
35.
FredholmBBCunhaRASvenningssonP (2003) Pharmacology of adenosine A2A receptors and therapeutic applications. Curr Top Med Chem3: 413–426.
36.
GarfinkelBDWebsterCDSlomanL (1975a) Methylphenidate and caffeine in the treatment of children with minimal brain dysfunction. Am J Psychiatry132: 723–728.
37.
GarfinkelBDWebsterCDSlomanL (1975b) Individual responses to methylphenidate and caffeine in children with minimal brain dysfunction. Can Med Assoc J113: 729–732.
38.
GarfinkelBDWebsterCDSlomanL (1981) Responses to methylphenidate and varied doses of caffeine in children with attention deficit disorder. Can J Psychiatry Rev Can Psychiatr26: 395–401.
GrahamJBanaschewskiTBuitelaarJ.; European Guidelines Group (2011) European guidelines on managing adverse effects of medication for ADHD. Eur Child Adolesc Psychiatry20: 17–37.
42.
GrantSJRedmondDEJr (1982) Methylxanthine activation of noradrenergic unit activity and reversal by clonidine. Eur J Pharmacol85: 105–109.
43.
HadfieldMGMilioC (1989) Caffeine and regional brain monoamine utilization in mice. Life Sci45: 2637–2644.
44.
HarveyDHPMarshRW (1978) The effects of de-caffeinated coffee versus whole coffee on hyperactive children. Dev Med Child Neurol20: 81–86.
45.
HolmgrenPNordén-PetterssonLAhlnerJ (2004) Caffeine fatalities—four case reports. Forensic Sci Int139: 71–73.
46.
HoltzmanSG (1987) Discriminative stimulus effects of caffeine: Tolerance and cross-tolerance with methylphenidate. Life Sci40: 381–389.
47.
HuestisRArnoldLESmeltzerDJ (1975) Caffeine versus methylphenidate and d-amphetamine in minimal brain dysfunction: A double-blind comparison. Am J Psychiatry132: 868–870.
48.
JainRHoltzmanSG (2005) Caffeine induces differential cross tolerance to the amphetamine-like discriminative stimulus effects of dopaminergic agonists. Brain Res Bull65: 415–421.
49.
JamesJE (2012) Death by caffeine: How many caffeine-related fatalities and near-misses must there be before we regulate?J Caffeine Res2: 149–152.
50.
KendlerKSMyersJGardnerCO (2006) Caffeine intake, toxicity and dependence and lifetime risk for psychiatric and substance use disorders: An epidemiologic and co-twin control analysis. Psychol Med36: 1717–1725.
LeonMR (2000) Effects of caffeine on cognitive, psychomotor, and affective performance of children with attention-deficit/hyperactivity disorder. J Atten Disord4: 27–47.
56.
LiuKLiangXKuangW (2011) Tea consumption maybe an effective active treatment for adult attention deficit hyperactivity disorder (ADHD). Med Hypotheses76: 461–463.
57.
McCarthySWiltonLMurrayML. (2012) Persistence of pharmacological treatment into adulthood, in UK primary care, for ADHD patients who started treatment in childhood or adolescence. BMC Psychiatry12: 219.
58.
MagonRMullerU (2012) ADHD with comorbid substance use disorder: Review of treatment. Adv Psychiatr Treat18: 436–446.
59.
MalinauskasBMAebyVGOvertonRF. (2007) A survey of energy drink consumption patterns among college students. Nutr J6: 35.
60.
MartinCACookCWoodringJH. (2008) Caffeine use: Association with nicotine use, aggression, and other psychopathology in psychiatric and pediatric outpatient adolescents. ScientificWorldJournal8: 512–516.
61.
MatiasAZimmerFJLorenzenA. (1993) Affinity of central adenosine A1 receptors is decreased in spontaneously hypertensive rats. Eur J Pharmacol244: 223–230.
62.
MercaderCPatelBP (2013) Caffeine abuse: The phantom differential in sleep complaints/disorders?J Subst Use18: 242–245
63.
MüllerCEJacobsonKA (2011) Recent developments in adenosine receptor ligands and their potential as novel drugs. Biochim Biophys Acta1808: 1290–1308.
64.
NuttDJFoneKAshersonP. (2007) Evidence-based guidelines for management of attention-deficit/hyperactivity disorder in adolescents in transition to adult services and in adults: Recommendations from the British Association for Psychopharmacology. J Psychopharmacol (Oxf)21: 10–41.
65.
PandolfoPMachadoNJKöfalviA. (2013) Caffeine regulates frontocorticostriatal dopamine transporter density and improves attention and cognitive deficits in an animal model of attention deficit hyperactivity disorder. Eur Neuropsychopharmacol23: 317–328.
66.
PinnaADi ChiaraGWardasJ. (1996) Blockade of A2a adenosine receptors positively modulates turning behaviour and c-fos expression induced by D1 agonists in dopamine-denervated rats. Eur J Neurosci8: 1176–1181.
67.
PiresVAPamplonaFAPandolfoP. (2009) Adenosine receptor antagonists improve short-term object-recognition ability of spontaneously hypertensive rats: A rodent model of attention-deficit hyperactivity disorder. Behav Pharmacol20: 134–145.
68.
PiresVAPamplonaFAPandolfoP. (2010) Chronic caffeine treatment during prepubertal period confers long-term cognitive benefits in adult spontaneously hypertensive rats (SHR), an animal model of attention deficit hyperactivity disorder (ADHD). Behav Brain Res215: 39–44.
69.
PomeranzJLMunsellCRHarrisJL (2013) Energy drinks: An emerging public health hazard for youth. J Public Health Policy. 34: 254–271.
70.
PousselMKimmounALevyB. (2013) Fatal cardiac arrhythmia following voluntary caffeine overdose in an amateur body-builder athlete. Int J Cardiol166: e41–42.
71.
PredigerRDSPamplonaFAFernandesD. (2005) Caffeine improves spatial learning deficits in an animal model of attention deficit hyperactivity disorder (ADHD) – the spontaneously hypertensive rat (SHR). Int J Neuropsychopharmacol8: 583–594.
72.
QuartaDFerréSSolinasM. (2004) Opposite modulatory roles for adenosine A1 and A2A receptors on glutamate and dopamine release in the shell of the nucleus accumbens. Effects of chronic caffeine exposure. J Neurochem88: 1151–1158.
73.
RapoportJLJensvoldMElkinsR. (1981) Behavioral and cognitive effects of caffeine in boys and adult males. J Nerv Ment Dis169: 726–732.
74.
ReichardCCElderST (1977) The effects of caffeine on reaction time in hyperkinetic and normal children. Am J Psychiatry134: 144–148.
75.
ReissigCJStrainECGriffithsRR (2009) Caffeinated energy drinks—A growing problem. Drug Alcohol Depend99: 1–10.
Rivera-OliverMDíaz-RíosM (2014) Using caffeine and other adenosine receptor antagonists and agonists as therapeutic tools against neurodegenerative diseases: A review. Life Sci101: 1–9.
78.
RogersPJHeatherleySVMullingsEL. (2013) Faster but not smarter: Effects of caffeine and caffeine withdrawal on alertness and performance. Psychopharmacology (Berl)226: 229–240
79.
RossDRossS (1982) Hyperactivity: Current Issues, Research, and Theory. 2nd ed.New York: Wiley.
80.
RussellVA (2002) Hypodopaminergic and hypernoradrenergic activity in prefrontal cortex slices of an animal model for attention-deficit hyperactivity disorder–the spontaneously hypertensive rat. Behav Brain Res130: 191–196.
81.
SawyerDAJuliaHLTurinAC (1982) Caffeine and human behavior: Arousal, anxiety, and performance effects. J Behav Med5: 415–439.
82.
SawynokJ (1995) Pharmacological rationale for the clinical use of caffeine. Drugs49: 37–50.
SchnackenbergRC (1973) Caffeine as a substitute for Schedule II stimulants in hyperkinetic children. Am J Psychiatry130: 796–798.
85.
SimolaNTronciEPinnaA. (2006) Subchronic-intermittent caffeine amplifies the motor effects of amphetamine in rats. Amino Acids31: 359–363.
86.
SimonVCzoborPBálintS. (2009) Prevalence and correlates of adult attention-deficit hyperactivity disorder: Meta-analysis. Br J Psychiatry J Ment Sci194: 204–211.
87.
TakahashiRNPamplonaFAPredigerRDS (2008) Adenosine receptor antagonists for cognitive dysfunction: A review of animal studies. Front Biosci J Virtual Libr13: 2614–2632.
88.
UkersWH (1922) All About Coffee. Tea and Coffee Trade Journal Company, New York
89.
WalkerLRAbrahamAATercyakKP (2010) Adolescent caffeine use, ADHD, and cigarette smoking. Child Health Care39: 73–90.
